NCT02178436View on ClinicalTrials.gov

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 27, 2021

Study Completion Date

April 5, 2023

Conditions
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasStage IV Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

Selinexor

Given IV

OTHER

Pharmacological Study

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab paclitaxel

Given IV

Trial Locations (2)

11794

Stony Brook University Cancer Center, Stony Brook

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

Mohammed Najeeb Al Hallak

OTHER

NCT02178436 - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter